

Generation and Evaluation of Clade C Simian-Human In Stocks

Journal of Virology

89, 1965-1974

DOI: [10.1128/jvi.03279-14](https://doi.org/10.1128/jvi.03279-14)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of SHIVs with circulating, transmitted HIV variants. Journal of Medical Primatology, 2015, 44, 296-300.	0.3	20
2	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	5.8	179
3	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	3.3	170
4	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	40
5	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nature Communications, 2017, 8, 14954.	5.8	176
6	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106
7	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	5.8	87
8	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	38
9	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nature Communications, 2017, 8, 1655.	5.8	142
10	Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy. Current Topics in Microbiology and Immunology, 2017, 417, 69-109.	0.7	14
11	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	2.1	28
12	High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses. PLoS ONE, 2018, 13, e0196942.	1.1	6
14	Recent progress in broadly neutralizing antibodies to HIV. Nature Immunology, 2018, 19, 1179-1188.	7.0	331
15	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying Env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. Journal of Virology, 2018, 92, .	1.5	3
16	Current advances in HIV vaccine preclinical studies using Macaque models. Vaccine, 2019, 37, 3388-3399.	1.7	16
17	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
18	Neutralizing antibodies for HIV-1 prevention. Current Opinion in HIV and AIDS, 2019, 14, 318-324.	1.5	34
19	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. Journal of Virology, 2020, 94, .	1.5	5

#	ARTICLE	IF	CITATIONS
20	Broadly neutralizing antibodies for HIV-1 prevention and therapy. <i>Seminars in Immunology</i> , 2021, 51, 101475.	2.7	28
21	Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. <i>Viruses</i> , 2021, 13, 397.	1.5	1
22	Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 712122.	2.2	43
24	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. <i>PLoS Pathogens</i> , 2016, 12, e1005431.	2.1	18
25	Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon- β Resistance. <i>PLoS Pathogens</i> , 2016, 12, e1005727.	2.1	10
26	Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes. <i>PLoS Pathogens</i> , 2018, 14, e1006902.	2.1	62
27	Conformation of HIV-1 Envelope Governs Rhesus CD4 Usage and Simian-Human Immunodeficiency Virus Replication. <i>MBio</i> , 2022, 13, e0275221.	1.8	3
28	CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection. <i>Retrovirology</i> , 2022, 19, .	0.9	5